Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
national top stories
6
×
new york blog main
san diego blog main
6
×
biotech
boston top stories
new york top stories
san diego top stories
san francisco blog main
clinical trials
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
ipo
national
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
cancer
deals
deerfield management
europe blog main
europe top stories
gene therapy
gilead sciences
What
medicines
6
×
drug
fda
ipo
new
ago
bio
covid
deal
diseases
genetic
rare
roundup
acquisitions
activity
aiming
akcea
alnylam
ambys
amgen
amyloidosis
announced
approval
approvals
approved
attr
available
battle
big
biogen
biotech
biotechs
candidates
ceo
clamped
class
collabs
considering
control
daniel
Language
unset
Current search:
medicines
×
" national top stories "
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines